Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 16,630 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $16.13, for a total value of $268,241.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) opened at $16.45 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64. Sangamo Therapeutics, Inc. has a 52 week low of $2.65 and a 52 week high of $18.40.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 26.03% and a negative net margin of 104.59%. The company had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the previous year, the firm posted ($0.27) earnings per share. The firm’s revenue for the quarter was up 333.0% on a year-over-year basis. equities research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.73 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of SGMO. RA Capital Management LLC bought a new stake in Sangamo Therapeutics during the second quarter worth approximately $11,000,000. State Street Corp boosted its position in shares of Sangamo Therapeutics by 51.6% during the second quarter. State Street Corp now owns 1,868,285 shares of the biopharmaceutical company’s stock valued at $16,441,000 after buying an additional 636,296 shares during the period. Vanguard Group Inc. boosted its position in shares of Sangamo Therapeutics by 12.4% during the second quarter. Vanguard Group Inc. now owns 3,471,681 shares of the biopharmaceutical company’s stock valued at $30,551,000 after buying an additional 384,031 shares during the period. Balyasny Asset Management LLC purchased a new position in shares of Sangamo Therapeutics during the second quarter valued at approximately $3,095,000. Finally, American Century Companies Inc. purchased a new position in shares of Sangamo Therapeutics during the third quarter valued at approximately $5,145,000. 64.35% of the stock is currently owned by institutional investors.
SGMO has been the topic of a number of recent analyst reports. Wells Fargo & Company reissued an “outperform” rating and set a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a report on Tuesday, September 5th. Jefferies Group reissued a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a report on Friday, October 13th. Piper Jaffray Companies raised Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a report on Wednesday, November 15th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a report on Wednesday, November 15th. Finally, Wedbush reaffirmed a “hold” rating and issued a $6.00 target price on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Sangamo Therapeutics currently has a consensus rating of “Buy” and an average price target of $17.83.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.